CMAN 272 Exam 3 | UPDATED Questions with 100% Verified
Answers
Q1: Acute Stress Disorder (ASD)
A: a disorder developing 3 days to 1 month after a major, traumatic stressor that causes
impairment
may develop into PTSD
best time to intervene!
Q2: Limbic System Response to Trauma
A: threat detection and memory of the event
Amygdala threat alarm
Hippocampus memory context
Hypothalamus SAM and HPA gateway
Prefrontal Cortex override from the thalamus (sensory relay)
Q3: SAM Axis Response to Trauma
A: sympathetic nervous system activation (F/F) and the release of adrenaline (epinephrine)
from adrenal glands
Q4: HPA Axis response to Trauma
A: Hypothalamus, Pituitary, Adrenal release of cortisol
Q5: PostTraumatic Stress Disorder
A: somatic, cognitive, affective, and behavioral effects from psychological trauma
Q6: PTSD symptoms clusters
A: Intrusion
Avoidance
Negative Cognition/Mood
Arousal/Reactivity
Q7: Intrusion
A: reexperiencing the raima
intense psychological distress and physiological reactions
,Q8: Avoidance
A: persistent avoidance of stimuli (memories, thoughts, feelings, external reminders...)
restructuring their lives
Q9: Negative Cognition/Mood
A: alterations in thoughts and feelings
dissociative amnesia inability to remember key aspects
negative beliefs and mood
Q10: Arousal/Reactivity
A: marked alteration in arousal
Self destruction, hypervigilance, startled, sleep disturbances
Q11: Pharmacological management of PTSD sleep disturbances
A: Prazosin (minipress)
Q12: Prazosin (minipress)
A: alpha 1 blocker, reducing hyperactivity
Q13: Gold standard treatment for PTSD
A: Eye Movement Desensitization and Reprocessing (EMDR)
Q14: EMDR
A: bilateral stimulation while processing traumatic memories to reduce emotional distress
Q15: What type of CBT is beneficial in PTSD
A: Trauma focused to address distorted thinking and avoidance behaviors
Q16: Depersonalization
A: persistent and recurrent detachment from self
Q17: Derealization
A: surrounding feel unreal
, Q18: Dissociative Amnesia
A: inability to recall important personal information that is too extensive for normal
forgetfulness
often related to trauma
Q19: Dissociative Identity Disorder (DID)
A: 2+ distinctive personality states or identities that recurrently control behavior
inability to recall personal information
strongly linked to childhood trauma (concurrent PTSD)
Q20: DID treatment
A: long term psychotherapy
mood stabilization with SSRIs and SGAs
Safety planning
Integrate the identities together!
Q21: Classification Categories of SubstanceRelated Disorders
A: Impaired Control
Social Impairment
Risky Use
Pharmacological (tolerance and withdrawl)
Q22: Impaired Control
A: Taking substances in larger amounts or over longer periods than was originally intended.
Desire or attempts to "cut down" or regulate (decrease or discontinue) use.
Spends a great deal of time obtaining, using or recovering from the effects of a
substance.
Cravings, or intense desire or "urge" to use a substance
Q23: Social Impairment
A: Failure to fulfil major role obligations
continued use despite persistent social or interpersonal problems
Giving up important activities
Q24: Risky Use
A: Recurrent use in physically hazardous situations
Continued use despite knowledge of physical/psychological problems
Q25: Pharmacological
A: Tolerance: need for increase dosage or lessened effect from same dose
Withdrawal: symptoms that are relieved by the substance
Answers
Q1: Acute Stress Disorder (ASD)
A: a disorder developing 3 days to 1 month after a major, traumatic stressor that causes
impairment
may develop into PTSD
best time to intervene!
Q2: Limbic System Response to Trauma
A: threat detection and memory of the event
Amygdala threat alarm
Hippocampus memory context
Hypothalamus SAM and HPA gateway
Prefrontal Cortex override from the thalamus (sensory relay)
Q3: SAM Axis Response to Trauma
A: sympathetic nervous system activation (F/F) and the release of adrenaline (epinephrine)
from adrenal glands
Q4: HPA Axis response to Trauma
A: Hypothalamus, Pituitary, Adrenal release of cortisol
Q5: PostTraumatic Stress Disorder
A: somatic, cognitive, affective, and behavioral effects from psychological trauma
Q6: PTSD symptoms clusters
A: Intrusion
Avoidance
Negative Cognition/Mood
Arousal/Reactivity
Q7: Intrusion
A: reexperiencing the raima
intense psychological distress and physiological reactions
,Q8: Avoidance
A: persistent avoidance of stimuli (memories, thoughts, feelings, external reminders...)
restructuring their lives
Q9: Negative Cognition/Mood
A: alterations in thoughts and feelings
dissociative amnesia inability to remember key aspects
negative beliefs and mood
Q10: Arousal/Reactivity
A: marked alteration in arousal
Self destruction, hypervigilance, startled, sleep disturbances
Q11: Pharmacological management of PTSD sleep disturbances
A: Prazosin (minipress)
Q12: Prazosin (minipress)
A: alpha 1 blocker, reducing hyperactivity
Q13: Gold standard treatment for PTSD
A: Eye Movement Desensitization and Reprocessing (EMDR)
Q14: EMDR
A: bilateral stimulation while processing traumatic memories to reduce emotional distress
Q15: What type of CBT is beneficial in PTSD
A: Trauma focused to address distorted thinking and avoidance behaviors
Q16: Depersonalization
A: persistent and recurrent detachment from self
Q17: Derealization
A: surrounding feel unreal
, Q18: Dissociative Amnesia
A: inability to recall important personal information that is too extensive for normal
forgetfulness
often related to trauma
Q19: Dissociative Identity Disorder (DID)
A: 2+ distinctive personality states or identities that recurrently control behavior
inability to recall personal information
strongly linked to childhood trauma (concurrent PTSD)
Q20: DID treatment
A: long term psychotherapy
mood stabilization with SSRIs and SGAs
Safety planning
Integrate the identities together!
Q21: Classification Categories of SubstanceRelated Disorders
A: Impaired Control
Social Impairment
Risky Use
Pharmacological (tolerance and withdrawl)
Q22: Impaired Control
A: Taking substances in larger amounts or over longer periods than was originally intended.
Desire or attempts to "cut down" or regulate (decrease or discontinue) use.
Spends a great deal of time obtaining, using or recovering from the effects of a
substance.
Cravings, or intense desire or "urge" to use a substance
Q23: Social Impairment
A: Failure to fulfil major role obligations
continued use despite persistent social or interpersonal problems
Giving up important activities
Q24: Risky Use
A: Recurrent use in physically hazardous situations
Continued use despite knowledge of physical/psychological problems
Q25: Pharmacological
A: Tolerance: need for increase dosage or lessened effect from same dose
Withdrawal: symptoms that are relieved by the substance
